FDA Announces Flexible Manufacturing Requirements for Cell and Gene Therapies to Accelerate Innovation
核心洞察
The FDA has announced increased regulatory flexibility for cell and gene therapy manufacturing requirements, reducing chemistry, manufacturing and control (CMC) barriers to expedite product development while maintaining quality standards.
The new approach allows looser quality controls during clinical trials, more flexible post-approval manufacturing specifications, and elimination of certain Process Performance Qualification requirements in specific cases.
These changes build on CBER's experience approving close to 50 cell and gene therapies (搜索) over the past decade and aim to address the explosive growth in CGT submissions targeting serious conditions with unmet medical needs.
The U.S. Food and Drug Administration announced on January 12, 2026, that it will implement more flexible chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (搜索) (CGTs), marking a significant shift in regulatory approach designed to accelerate innovation while maintaining rigorous quality standards.
"Regulatory flexibility must be tailored for cell and gene therapies (搜索)," said FDA Commissioner Marty Makary, M.D., M.P.H. "These are common-sense reforms that will address the unique characteristics of cell and gene therapies and foster more innovation."
Regulatory Changes Address Unique Manufacturing Challenges
The FDA's Center for Biologics Evaluation and Research (搜索) (CBER) has implemented flexibility in three key areas of CGT manufacturing oversight. First, manufacturers may now be subject to looser quality controls during later efficacy-focused trials, similar to those typically applied in earlier safety-focused studies. Companies can also implement minor changes to production between Phase I and Phase II trials when supported by sufficient data.
Second, the agency will consider more flexible post-approval manufacturing controls for Biologics License Applications (BLAs) for CGTs, with quality specifications that may be revised after approval. Finally, the FDA has eliminated the requirement for three rounds of Process Performance Qualification (PPQ) before commercial production in certain cases, while allowing PPQ details to be designed on a batch-by-batch basis.
These changes recognize that CGTs are inherently complex biologic products, often individualized for patients, requiring sophisticated manufacturing under particular time constraints. CAR-T therapies (搜索) for blood cancers (搜索), for example, involve harvesting cells from patients, modifying them, growing them in culture, and reinfusing them within days or weeks.
Building on Decade of Experience
Over the past decade, CBER has approved close to 50 CGTs, leveraging this growing experience to identify regulatory flexibilities that accommodate the unique characteristics of these innovative therapies. "There has been tremendous enthusiasm amongst product developers resulting in an explosive growth of cell and gene therapy submissions, many of which target serious or life-threatening conditions with an unmet medical need," said Vinay Prasad, M.D., M.P.H., Chief Medical and Scientific Officer and Director of CBER.
Previously, CBER applied similar CMC expectations across products, including small-batch products such as CGTs. The agency has now moved from case-by-case flexibility to a more structured framework that can be communicated proactively to expedite product development across the CGT field.
"CBER is proactively communicating about regulatory flexibilities that were previously applied case-by-case to select CGT therapies," said Vijay Kumar M.D., Acting Director, Office of Therapeutic Products in CBER. "By communicating these approaches broadly, we aim to expedite product development across the CGT field."
Supporting Personalized Medicine Innovation
The new requirements support the "plausible mechanism pathway" outlined by Makary and Prasad in the New England Journal of Medicine in November 2025. This pathway aims to accelerate approvals for personalized therapies where well-characterized underlying abnormalities can be addressed amid unmet need, provided targets can be confirmed through modeling and improved clinical outcomes established.
The pathway was inspired by the case of Baby KJ, a newborn with carbamoyl phosphate synthase 1 (搜索) (CPS1) deficiency, a rare disorder affecting protein digestion. In May 2025, Baby KJ's care team manufactured a custom CRISPR (搜索) treatment to repair the underlying mutation in just one week, making him the world's first to receive a bespoke CRISPR therapy.
Industry Context and Future Outlook
Despite some developers abandoning CGT projects in recent months, including Belgian biotech Galapagos and Japanese pharma Takeda (搜索) dropping their cell therapy efforts in late 2025, the regulatory changes reflect the agency's commitment to removing barriers that stand in the way of expedited product development.
The FDA hosted a Cell and Gene Therapy Roundtable in June, bringing together leading experts to discuss advancing the field. Health and Human Services secretary Robert F Kennedy Jr. held a roundtable of CGT experts on June 5, where he committed to fast-track approvals for rare disease treatments.
These flexibilities are designed to enable progress while not compromising the FDA's ability to assure safety, purity and potency of products, or weakening the agency's understanding of the benefits and risks of both specific therapies and disease contexts.